STOCK TITAN

Sera Prognostics, Inc. - SERA STOCK NEWS

Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.

Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.

Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.

As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.

Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.

For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.

Rhea-AI Summary

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), reported its first-quarter 2024 financial results, focusing on improving maternal and neonatal health through innovative pregnancy biomarker information. The company highlighted submitting PRIME study interim analysis results for publication, launching ambient whole blood collection kits to reduce costs and increase lab processing efficiency, and expanding into international markets. Despite revenue adjustments, operational expenses decreased, resulting in a narrower net loss compared to the same quarter in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
-
Rhea-AI Summary

Sera Prognostics Inc., a company focused on improving maternal and neonatal health, will report first quarter fiscal year 2024 financial results on May 8, 2024. The conference call and webcast will discuss operational highlights, financial results, and key topics at 5:00 p.m. Eastern Time. Details for the call are provided for both US domestic and international callers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
-
Rhea-AI Summary
Sera Prognostics Inc. (SERA) announced financial results for Q4 and full year 2023, highlighting the positive recommendation to stop enrollment in their PRIME study due to efficacy. The company is preparing to publish study results and launch new products to enhance revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
Rhea-AI Summary
Sera Prognostics Inc. (NASDAQ: SERA) will report Q4 and full year 2023 financial results on March 20, 2024. The company focuses on pregnancy biomarker information for maternal and neonatal health. A conference call will discuss operational highlights and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
Rhea-AI Summary
Sera Prognostics Inc. (NASDAQ: SERA) will present at the TD Cowen 44th Annual Healthcare Conference to discuss its latest achievements in improving maternal and neonatal health through innovative pregnancy biomarker information. Zhenya Lindgardt, President and CEO, will provide a company update in a fireside chat on March 4, 2024, at 2:50 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences
-
Rhea-AI Summary
Sera Prognostics Inc. (Nasdaq: SERA) announced that the DSMB recommended stopping enrollment for its PRIME study due to efficacy, with both co-primary endpoints meeting stopping criteria for statistical significance at the pre-planned interim analysis. The company will focus on analyzing and reporting available data, with President and CEO Zhenya Lindgardt expressing excitement over the report of efficacy from the DSMB.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
161.43%
Tags
Rhea-AI Summary
Sera Prognostics Inc. (SERA) will present at the 35th Annual Piper Sandler Healthcare Conference on November 28, 2023. Doug Fisher, Sera's Chief Business Officer, will participate in a presentation at 10:50 a.m. ET. The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
conferences
-
Rhea-AI Summary
Sera Prognostics Inc. (SERA) announced financial results for Q3 2023, highlighting cost reduction activities, care coordination offering, and positive clinical trial findings. The company reported $42,000 in revenue, with total operating expenses of $8.2 million and a net loss of $7.2 million. Sera Prognostics had cash, cash equivalents, and available-for-sale securities of approximately $85.0 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.61%
Tags
-
Rhea-AI Summary
Sera Prognostics Inc. will report Q3 FY2023 financial results on November 8, 2023, after the market close. The company will host a conference call and webcast to discuss operational highlights and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
Rhea-AI Summary
Sera Prognostics Inc. to present at Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
conferences

FAQ

What is the current stock price of Sera Prognostics (SERA)?

The current stock price of Sera Prognostics (SERA) is $6.54 as of November 22, 2024.

What is the market cap of Sera Prognostics (SERA)?

The market cap of Sera Prognostics (SERA) is approximately 218.8M.

What is Sera Prognostics' main product?

The main product of Sera Prognostics is the PreTRM® Test, a blood-based biomarker test for predicting the risk of preterm birth.

Where is Sera Prognostics headquartered?

Sera Prognostics is headquartered in Salt Lake City, Utah.

What is the mission of Sera Prognostics?

Sera Prognostics aims to improve maternal and neonatal health by providing early, pivotal pregnancy information to doctors and patients.

Who are some of the major investors in Sera Prognostics?

Major investors include the Bill & Melinda Gates Foundation, Domain Associates, InterWest Partners, and more.

What recent financial milestone has Sera Prognostics achieved?

Sera Prognostics has been added to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes.

How does the PreTRM® Test work?

The PreTRM® Test measures proteins in the blood during weeks 18-20 of pregnancy to predict the risk of spontaneous preterm birth.

What are the benefits of the PreTRM® Test?

The PreTRM® Test allows for early, individualized risk assessment of preterm birth, enabling proactive healthcare interventions to improve outcomes.

What strategic partnerships does Sera Prognostics have?

Sera Prognostics collaborates with the Bill & Melinda Gates Foundation to make its diagnostic technologies accessible in underserved regions.

What are the company's future plans for expanding its product offerings?

Sera Prognostics plans to enhance its product pipeline with new diagnostic tests and ambient whole blood collection methods to increase efficiency and reduce costs.

What challenges does Sera Prognostics face?

Challenges include achieving broad scientific and market acceptance of the PreTRM® Test, potential competition, and securing third-party payer coverage and reimbursement.

Sera Prognostics, Inc.

Nasdaq:SERA

SERA Rankings

SERA Stock Data

218.83M
28.54M
11.99%
71.57%
3.09%
Medical Devices
Services-medical Laboratories
Link
United States of America
SALT LAKE CITY